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Introduction: Nonoperative treatment of stage III non-small cell lung
cancer has evolved over the past 30 years. The current approach in the
Unites States most often includes concurrent chemoradiotherapy.
Methods: We have used live, case-based research events to docu-
ment prescribing plans among American medical oncologists for
first-line therapy in patients with N3 stage IIIB non-small cell lung
cancer. Changes in prescribing plans documented before and after
the 2007 American Society of Clinical Oncology (ASCO) presen-
tation of a Hoosier Oncology Group trial testing the role of consol-
idation docetaxel chemotherapy in this setting are presented.
Results: Data from 2007 show a post-ASCO shift away from plans
for docetaxel consolidation, increased use of concurrent chemora-
diotherapy alone, and stable to increased plans for concurrent
chemoradiation followed by additional cycles of the chemotherapy
used during concurrent management (20%). Preliminary data from
2008 confirm the durability of these changes.
Conclusions: The findings of the Hoosier Oncology Group trial
support a transition away from docetaxel consolidation. A trend in
this direction among American medical oncologists is clear from our
data. However, nearly 20% of oncologists studied in 2008 still plan to
use docetaxel consolidation. Furthermore, a majority of those studied
after ASCO 2007 continue to report plans to use more than two cycles
of chemotherapy as part of their preferred treatment recommendation
despite no level I evidence to support this approach.
Key Words: Non-small cell lung cancer, Stage III, Chemoradio-
therapy, Consolidation chemotherapy, Phase III trial.
(J Thorac Oncol. 2009;4: 983–987)
The most recent figures from the American Cancer Societysuggest that we should expect 215,000 new cases of lung
cancer in 2008. Approximately 85% of these new cases will
have nonsmall cell histology and about one third will have
regional (N2–N3) disease at the time of diagnosis.1 Based on
these figures, nearly 64,000 individual Americans should be
identified with stage III non-small cell lung cancer (NSCLC)
during this calendar year.
Nonoperative treatment of stage III NSCLC has
evolved during the past 30 years from largely palliative
radiation therapy, through sequential chemotherapy followed
by radiation, to the current use of concurrent chemoradiother-
apy.2 In many cases, physicians have used two to four
additional chemotherapy cycles as either induction or consol-
idation therapy with the expectation that the added chemo-
therapy would improve survival. In 2006, data from a Cancer
and Leukemia Group B randomized phase III trial failed to
demonstrate a survival advantage for the addition of two
cycles of full-dose carboplatin-paclitaxel followed by defin-
itive radiation and concurrent weekly paclitaxel-carboplatin
compared with definitive radiation and concurrent weekly
paclitaxel-carboplatin alone.3 However, up until recently,
phase II data reported by multiple investigators suggested that
immediate concurrent chemoradiotherapy followed by con-
solidation chemotherapy produced excellent outcomes for
nonoperative therapy in stage III patients. One such approach
developed by Southwest Oncology Group (SWOG) investi-
gators involved immediate concurrent etoposide-cisplatin and
radiotherapy followed by three cycles of docetaxel.4 Another
approach using immediate concurrent carboplatin-paclitaxel
radiation followed by two additional cycles of every 3-week
paclitaxel-carboplatin was reported by Belani et al.5 Data on
978 American medical oncologists studied by investigators at
Network for Medical Communications and Research
(NMCR) Analytics between 2005 and before the 2007 Amer-
ican Society of Clinical Oncology (ASCO) Annual Meeting
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showed that nearly 70% planned to use both concurrent che-
moradiation and consolidation chemotherapy in this setting.6
At the 2007 ASCO meeting, investigators from the
Hoosier Oncology Group7 (HOG) reported that there was no
survival advantage but significant toxicity from the addition
of docetaxel consolidation to immediate radiation and con-
current etoposide-cisplatin (Figure 1). To assess the impact of
these data, we documented the prescribing plans for nonop-
erative therapy for patients with N3 stage IIIB NSCLC
among several hundred additional American medical oncolo-
gists. Here, we report those prescribing plans and discuss the
impact of new phase III data on treatment strategies planned
for patients with stage IIIB NSCLC.
METHODS
Since 2005, NMCR Analytics has studied prescribing
plans of American medical oncologists for patients with stage
III NSCLC using 14 individual live research events. Physi-
cians participating in these research programs self-register
through direct invitation or by means of the NMCR Analytics
website. Attendees are reimbursed for research-related ex-
penses including any travel costs incurred and specific out-
of-pocket expenses. Attendees do not receive additional pay-
ments for their participation. Responses to research queries are
treated confidentially, and no identifying information about
individual participants is disclosed. Attendees may participate in
only one lung cancer research event within a calendar year.
Some of the prescribing plans recorded in the first two research
events of 2008 may come from individuals also included in the
prescribing plans tallied pre-ASCO 2007 or post-ASCO 2007.
Research programs are designed to mimic real-life
clinical scenarios. The hypothetical case history is projected
on the screen at the front of the meeting room and read aloud
by the research event moderator. Treatment plan options (up
to 10) are then offered, and physician selections are acquired
anonymously and contemporaneously by keypad and elec-
tronic data capture before any discussion of relevant data
supporting one or more of the possible prescribing plans
offered. As soon as the participants have completed their
selection (documented by real-time counter of responses), the
results are tallied and projected in bar graph format.
Demographic information is collected from the partic-
ipants at the beginning of each research session. The charac-
teristics polled include practice venue (academic versus com-
munity and geographic region), number of partners, years
from completion of training in oncology, number of new lung
cancer patients seen each month, sex, and participation in a
group purchasing organization. These features are entered
into the wireless keypad by each attendee in response to
specific questions. This information then gives each keypad a
demographic character that can be used to analyze the re-
spondent choices by subset while maintaining the anonymity
of the individual participants.
To study current approaches in a patient with N3 stage
IIIB NSCLC, we used a core case history and a “menu” of
preset treatment plans (Figures 2, 3). Oncologists are very
familiar with this approach. Case-based decision making is
the standard format for tumor board or clinical case confer-
ence discussions of potential management options for indi-
vidual patients. Although this format cannot encompass all
possible treatment plans among the options offered (10),
we include a broad range of relevant options including all
relevant evidence-based strategies. An option of “other” is
also included to avoid a forced choice. Not all attendees
respond to every research question posed, but overall
participation of more than 80% is achieved for each
question.
FIGURE 1. Schema for Hoosier Oncology Group (HOG)
trial evaluating the role of docetaxel consolidation in pa-
tients with a new diagnosis of stage III non-small cell lung
cancer (NSCLC).
A 66-year-old former smoker has a progressive cough. After an episode of 
hemoptysis (actually only a small amount of bloody sputum) he is seen in the ER 
where a chest x-ray and chest CT are done. There is a partially cavitated, 
medially located, RUL mass with enlarged hilar and N2 and N3 mediastinal 
nodes. A pulmonary medicine physician sees him and arranges an urgent 
bronchoscopy (TBB specimen positive for NSCLC NOS) and Wang needle 
aspiration of subcarinal nodes (also + for tumor). A PET scan is positive in these 
areas as well as the right hilum and the right and left paratracheal areas. A head 
MRI is negative for metastatic disease. 
FIGURE 2. Case scenario for assessing prescribing plans of
American medical oncologists. No changes were made in
the case scenario during the entire period reported.
1. Immediate TRT followed by (f/by) CT 
2. Induction CT f/byTRT  
3. 2 cycles of induction CT f/by CT/TRT (same drugs as in induction) 
4. CT/TRT (no induction or consolidation CT) 
5. CT/TRT f/by 2 added cycles of the same CT used during radiation 
6. CT/TRT f/by 3 doses of docetaxel 
7. CT/TRT f/by 3 doses of docetaxel and then single agent erlotinib. 
8. CT alone 
9. Other  
TRT = Thoracic radiotherapy; CT = Chemotherapy; CT/TRT = concurrent 
chemoradiotherapy 
FIGURE 3. Prescribing plans offered as selection options for
the research study participants. The option “other” is rou-
tinely included to avoid driving research participants to a
“forced choice” selection.
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RESULTS
Between March 2005 and May 2007, 978 medical
oncologists participated in 12 live research events studying
prescribing plans for different clinical settings in lung cancer.
These individuals and those queried after the 2007 ASCO
meeting were 80% self-identified as “community based”
and displayed a geographic spread reflective of the broad
American Oncology workforce. Less than 25% were in solo
practice, and a majority of all respondents were more than 10
years out from completion of their oncology training.
In the assessment of prescribing plans for the stage IIIB
setting, a substantial majority of the 978 responding physi-
cians planned to use concurrent chemoradiotherapy followed
by additional chemotherapy (Figure 4). For 47% of physi-
cians, the planned therapy was immediate chemoradiation
followed by three doses of docetaxel consolidation. For 3%,
the plan included the same chemoradiation followed by three
doses of docetaxel consolidation and then additional mainte-
nance therapy with an oral antiepidermal growth factor re-
ceptor tyrosine kinase inhibitor. An additional 17% of re-
spondents favored the use of immediate chemoradiotherapy
followed by two additional cycles of the same chemotherapy
used during the concurrent phase of treatment.
In 2007, we studied an additional 427 physicians (pre-
set participation goal 400) in five live research events held
between March and September. Demographic characteristics
of these research participants were similar to those of the
earlier 987 physician cohort. These research events again
used the same clinical scenario of stage IIIB disease and
offered the same panel of therapy options. In Figure 5, the
aggregate findings of the five research events of 2007 are
shown, whereas in Figure 6, the data are broken down by
pre-ASCO 2007 and post-ASCO 2007. The aggregate data do
show a shift away from the use of immediate chemoradio-
therapy followed by docetaxel consolidation (38%), a rise in
the use of immediate concurrent chemoradiotherapy alone
(20%), and stable plans for use of immediate concurrent
chemoradiation followed by two additional cycles of the
same chemotherapy that was used in the concurrent phase of
therapy (19%). However, the aggregate data (Figure 5) ob-
scure a more dramatic time-dependent movement away from
docetaxel consolidation (45% 3 27%; 2 p  0.0002) and
toward immediate concurrent chemoradiotherapy without
consolidation, the strategies compared directly in the HOG
phase III trial.
In Figure 7, the 2007 data from each of the five research
events are displayed individually. Presenting the data in this
fashion further highlights the change driven by the 2007
ASCO presentation of the HOG trial data. Immediately after
ASCO 2007, a shift in prescribing plans occurred. Its dura-
bility and further amplification are evident in the data from
late September. After the acquisition of these data, we con-
tinued to monitor prescribing plans in 2008 (Table 1). In two
research events in February and April 2008, plans for use of
FIGURE 4. Prescribing plans for a patient with a new diag-
nosis of stage IIIB non-small cell lung cancer (NSCLC) as-
sessed in 987 American medical oncologists who partici-
pated in Network for Medical Communications and Research
(NMCR) live research events between March 2005 and May
2007.
FIGURE 5. Prescribing plans for a patient with a new diag-
nosis of stage IIIB non-small cell lung cancer (NSCLC) as-
sessed in 427 American medical oncologists who partici-
pated in Network for Medical Communications and Research
(NMCR) live research events between March and September
2007.
FIGURE 6. Prescribing plans for a patient with a new diag-
nosis of stage IIIB non-small cell lung cancer (NSCLC) as-
sessed in 427 American medical oncologists who partici-
pated in Network for Medical Communications and Research
(NMCR) live research events between March and September
2007. Prescribing plans shown for two time frames, before
and after American Society of Clinical Oncology (ASCO)
2007. Choices of “radiation followed by chemotherapy,”
“chemotherapy alone,” and “other,” totaling 3% are not
shown here.
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consolidation docetaxel have fallen to less than 20% of
research respondents. The largest single group now plans
to use immediate concurrent chemoradiotherapy without
either induction or consolidation. However, the ambiva-
lence of the treating oncology community is clear, with a
majority of all respondents planning some treatment strat-
egy that includes more than just two cycles (or equivalent)
of chemotherapy during radiation as total therapy in the
stage IIIB setting.
DISCUSSION
Individuals diagnosed with a contralateral-mediastinal,
N3, stage IIIB NSCLC are seeking the best therapy option to
provide them with the longest duration of quality life. They
recognize that there may be some individual potential to
achieve long-term disease control, although the best strategy
for optimizing this goal is unclear. For fit individuals with a
diagnosis of N3, stage IIIB NSCLC, the treatment recom-
mendations of American medical oncologists almost always
involve both chemotherapy and radiation. These two modal-
ities are designed to both maximize control of the macro-
scopic locoregional disease and eradicate micrometastatic
foci that are also highly likely to be present. Currently, phase
III trial data from numerous sources suggest that use of
concurrent chemoradiotherapy can increase overall survival
when compared directly with the same therapies given se-
quentially. The survival advantage is modest however, and
there are additional toxicities associated with concurrent
rather than sequential management.2
The potential of chemotherapy to effectively eradicate
micrometastases and improve survival when used in the
adjuvant setting has been demonstrated among patients with
many different types of solid tumors including NSCLC.8 In
almost all these settings (testis cancer being a notable solid
tumor exception), the adjuvant chemotherapy prescription
has included more than two cycles of chemotherapy. Thus,
when approaching an individual with more disease (e.g.,
stage IIIB NSCLC) and the expectation that the burden of
micrometastatic disease is likely to be at least as great if not
greater than in the traditional adjuvant setting, investigators
and treating physicians have tended to favor strategies using
more than two cycles of chemotherapy as part of definitive
management.2 Yet, no randomized phase III data are avail-
able to endorse this approach in stage III NSCLC. However,
as demonstrated here, before ASCO 2007 the use of more
than two cycles of chemotherapy was the overwhelming plan
of American medical oncologists treating patients with N3,
stage IIIB disease. For nearly 70%, the additional chemother-
apy was planned as consolidation and for most of those the
consolidation involved use of single-agent docetaxel. This
approach was supported by impressive multiinstitutional
phase II data provided by investigators from the SWOG. In
their phase II work (SWOG 9504),4 the median survival
achieved with immediate concurrent etoposide-cisplatin and
thoracic radiation followed by three cycles of docetaxel
consolidation was 26 months and the 3- and 5-year survival
rates were 40% and 29%, respectively.4 In a previous SWOG
study in patients with stage III disease using the same initial
chemoradiotherapy but followed by consolidation with two
added cycles of etoposide and cisplatin, the median survival
was 15 months and 3- and 5-year survival rates were 17%.9
These phase II findings and informal comparison generated
major enthusiasm for the SWOG 9504 approach. After
lengthy discussions with representatives from the National
Cancer Institute’s Cancer Therapy Evaluation Program, the
follow-up phase III trial proposed by SWOG investigators to
confirm the benefit of consolidation docetaxel that was im-
plied by their sequential phase II trials was not approved.
Instead, an alternative design that presumed a benefit from
consolidation docetaxel and tested the value of maintenance
gefitinib (SWOG S0023) was moved forward.10
At ASCO 2007, findings from the HOG phase III
(albeit modest in size) trial testing immediate concurrent
FIGURE 7. Prescribing plans for a patient with a new diag-
nosis of stage IIIB non-small cell lung cancer (NSCLC) as-
sessed in 427 American medical oncologists who partici-
pated in Network for Medical Communications and Research
(NMCR) live research events between March and September
2007. Prescribing plan data are shown for each specific re-
search event with the inflection point coinciding with the
Hoosier Oncology Group (HOG) data presentation at Ameri-
can Society of Clinical Oncology (ASCO) 2007.
TABLE 1. Prescribing Plan Data from Research Events Held
in February 2008 and April 2008 Demonstrate the Persisting
Shift Away from Use of Docetaxel Consolidation After ASCO
2007
Regimen
February 23, 2008,
n  109 (%)
April 05, 2008,
n  61 (%)
CT/TRT 1 5
CT-CT/TRT 8 10
CT/TRT (HOG) 39 44
CT/TRT-same CT (LAMP) 26 23
CT/TRT-doc (SWOG 9504) 19 18
CT/TRT-doc-erlotinib (0023) 3 0
CT alone 1 0
Other 1 0
CT/TRT, chemotherapy/thoracic radiotherapy; HOG, Hoosier Oncology Group;
LAMP, locally advanced multi-modality protocol; SWOG, Southwest Oncology Group.
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chemoradiotherapy as used by SWOG with or without do-
cetaxel in patients with stage III NSCLC were presented by
Hanna et al.7 Although some of the patients included in this
study had baseline characteristics, especially less optimal
pulmonary function, that were different from the SWOG
study participants, the core comparison of CT/TRT with or
without consolidation addressed the critical question of
whether the addition of consolidation chemotherapy would
significantly improve the survival outcome in patients with
stage III NSCLC. The data from the 2007 presentation were
clear. In every relevant treatment-efficacy comparison there
was no improvement, let alone no significant benefit, for the
addition of docetaxel consolidation. At ASCO 2008, further
follow-up of the HOG trial again showed no benefit from
docetaxel consolidation.11 However, the 2007 presentation
did highlight the toxicity risks associated with docetaxel
consolidation. These included a 24.7% rate of grade 3 or 4
neutropenia, a 10.9% rate of febrile neutropenia, an 8.2%
rate of grade 3 pneumonitis, and a 5.5% treatment related
death rate.
The findings of the HOG trial support a transition
away from docetaxel consolidation,12 and the trend in this
direction among American medical oncologists is clear
from our data. However, two surprising results of our
research are evident. First and foremost, nearly 20% of
those oncologists studied in 2008 are still planning a
SWOG 9504 approach with docetaxel consolidation. This
seems difficult to justify in light of the toxicity produced
by this strategy and the failure of the phase III comparison
to suggest any benefit. Whether the SWOG Lung commit-
tee will decide to retest a chemoradiotherapy followed by
consolidation strategy remains to be seen. More globally,
a majority of all the oncologists studied after ASCO 2007
continue to report plans to use more than two cycles of
chemotherapy as part of their preferred treatment recom-
mendation for fit patients with stage III NSCLC. For the
largest single subgroup of those oncologists, the preferred
recommendation now involves immediate induction che-
moradiotherapy followed by two added cycles of the same
chemotherapy in the consolidation setting. Although this
decision is consistent with the model of adjuvant chemo-
therapy widely applied in patients with completely re-
sected solid tumors, there are no phase III data in the lung
cancer setting to support it, and the toxicity risks and
economic costs associated with it are formidable. Cur-
rently, there are no plans among the American National
Cancer Institute sponsored cooperative groups to retest the
role of chemotherapy consolidation, e.g., immediate con-
current chemoradiation with or without two added cycles
of the same chemotherapy as consolidation. Although such
a trial would add to the evidence base in stage III disease,
there are scant to no compelling phase II data that support
such a resource-intensive undertaking.
The changing approach to definitive nonoperative
management of patients with stage III NSCLC is clearly
demonstrated by our research. We will continue to monitor
prescribing plans proposed by American medical oncolo-
gists for patients with regionally advanced NSCLC. It is
hoped that the trends away from docetaxel consolidation
will continue. This is a critical setting in which patients
with a new diagnosis of stage III NSCLC and their treating
oncologists should come together to participate in well-
designed clinical trials with the potential to generate new
leads or definitive data concerning better approaches to
achieve the jointly shared goal of a longer duration of
quality life and an enhanced opportunity for long-term
disease control.
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